Five Multiple Sclerosis R&D Updates From ECTRIMS
Executive Summary
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
You may also be interested in...
Novartis’s Tschudin On Launches, Drug Pricing And Lasting COVID Impacts
Two years into leading Novartis' largest business unit, Novartis Pharmaceuticals president Marie-France Tschudin talked to Scrip about the US launch of inclisiran, US drug price reform and other challenges and opportunities for the industry.
Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS
BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.
Janssen’s Ponvory Will Face Stiff Competition In Europe’s MS Market
Janssen is the latest big pharma company to gain an approval for a new oral multiple sclerosis therapy in the EU, enhancing the competitiveness of the marketplace, and giving more choice for patients.